INT318804

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.33
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (CLU) endoplasmic reticulum (CLU) lipid metabolic process (CLU)
cytoplasm (CLU) cytosol (CLU) extracellular space (CLU)
CLU (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 16 5.00 Very Low Very Low Very Low
antagonist 12 5.00 Very Low Very Low Very Low
positron emission tomography 10 5.00 Very Low Very Low Very Low
palliative 4 5.00 Very Low Very Low Very Low
cva 4 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
Analgesic 2 5.00 Very Low Very Low Very Low
peripheral neuropathy 2 5.00 Very Low Very Low Very Low
agonist 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Recurrence 4 99.98 Very High Very High Very High
Prostate Cancer 222 97.36 Very High Very High Very High
Thrombocytopenia 4 81.16 Quite High
Mucositis 2 80.28 Quite High
Fatigue 8 79.84 Quite High
Immunotherapy Of Cancer 2 29.24 Quite Low
Death 12 25.56 Quite Low
Apoptosis 8 24.20 Low Low
Cancer 56 5.00 Very Low Very Low Very Low
Disease 44 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Several studies have demonstrated clusterin overexpression in prostate cancer especially after hormone therapy.13,39 Clustein expression has also reported to be a possible predictor for biochemical recurrence following prostatectomy.14 An antisense oligonucleotide directed against clusterin (custirsen, OGX-011) has been developed, and successful downregulation of clusterin expression was shown in primary prostate cancers in a phase I study.40
Negative_regulation (oligonucleotide) of Localization (directed) of clusterin associated with prostate cancer and recurrence
1) Confidence 0.18 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 0.66 Pain Relevance 0
Several studies have demonstrated clusterin overexpression in prostate cancer especially after hormone therapy.13,39 Clustein expression has also reported to be a possible predictor for biochemical recurrence following prostatectomy.14 An antisense oligonucleotide directed against clusterin (custirsen, OGX-011) has been developed, and successful downregulation of clusterin expression was shown in primary prostate cancers in a phase I study.40
Negative_regulation (following) of Localization (directed) of clusterin associated with prostate cancer and recurrence
2) Confidence 0.18 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 0.67 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox